A novel combination therapy for treating vancomycin-resistant bacterial infections

Researchers developed a combination therapy using the anticancer agent mitoxantrone (MTX), together with an antibiotic, vancomycin, for treating vancomycin-resistant Enterococcus faecalis or VRE.

Related Keywords

Geneva ,Genè ,Switzerland ,Singapore ,Jianzhu Chen ,National Research Foundation Of Singapore ,Nanyang Technological University ,Innovation Centre ,Alliance For Research ,Campus For Research Excellence ,Koch Institute For Integrative Cancer Research ,Singapore Centre For Environmental Life Sciences Engineering ,University Of Geneva ,Energy Electronic Systems ,Antimicrobial Resistance ,Singapore Centre ,Environmental Life Sciences Engineering ,Koch Institute ,Integrative Cancer ,National Research Foundation ,Research Excellence ,Technological Enterprise ,Critical Analytics ,Manufacturing Personalized Medicine ,Sustainable Technologies ,Agricultural Precision ,Future Urban Mobility ,Low Energy Electronic ,Smart Amr ,Ingapore Mit Alliance For Research And Technology ,Ntimicrobial Resistance Interdisciplinary Research Group Amr Irg ,Antimicrobial Resistance Amr ,Itoxantrone ,Ancomycin Resistant Enterococcus Faecalis Vre ,Tx Research ,Ancomycin Resistance ,Tianzhu Chen ,